Входя на эту страницу, Вы подтверждаете, что являетесь  медицинским работником.

Status message

Not the entire site translated, but only to "Magazine"

FEATURES DYSLIPIDEMIAS DISORDERS IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH HALOPERIDOL AND RISPERIDONE, DEPENDING ON THE CARRIER STATE OF SOME GENETIC POLYMORPHISMS

M.S. Shtan 1, 2, A.S. Ozornin 1, 2, N.V. Govorin 3

1 Chita state medical Academy, Chita, Russia
2 V. Kh. Kandinsky Territorial Clinical Psychiatric Hospital, Chita, Russia
3State Duma of the Federal Assembly of the Russian Federation, Moscow, Russia

Annotation.
Objective – to determine the role of polymorphism of some genes in the development of dyslipidemic disorders in psychopharmacotherapy in patients with paranoid schizophrenia.
Materials and methods: 80 patients with first episode paranoid schizophrenia and 70 healthy individuals.
Research methods: molecular genetic, biochemical, statistical.
Results: it was found that carriers of the genotype Gln/Gln polymorphism Arg223Gln of the LEPR gene predominate among patients. Have been identified the risks of developing dyslipidemias disorders in carriers of the mutant allele A of gene polymorphism АРОА1 and allele G of gene АРОС3 in schizophrenic patients. It was revealed that in the carriers of these alleles the risks of development of dyslipidemic disorders increase during antipsychotic therapy.
Conclusions: at the beginning of paranoid schizophrenia, the risk of development of dyslipidemic disorders in carriers of different genotypes of AROA-1 and AROS3 genes was revealed. In addition, a group of genetically vulnerable individuals with respect to lipid metabolism disorders against the background of receiving antipsychotics was established.

CONTACT: solopova-mari@mail.ru

References: 

1. Virshing D.A. Shizofreniyaiozhirenie: vliyanieantipsihoticheskihpreparatov // Social'nayaiklinicheskayapsihiatriya. – 2007. – T. 17, № 4. – S. 45–58.

2. Volkov V.P. Kardiologicheskieprichinysmertibol'nyhshizofreniej // Social'nayaiklinicheskayapsihiatriya. – 2012. – T. 22, № 4. – S. 41–45.

3. Bardenshtejn L.M., Mkrtumyan A.M., Aleshkina G.A. Sostoyanieuglevodnogoilipidnogoobmena u bol'nyhparanoidnojshizofreniejpriterapiiatipichnymiantipsihoticheskimipreparatami // Saharnyjdiabet. – 2010. – № 2. – S. 42–44.

4. Feng S, Melkersson K. Metabolic parameters and long-term antipsychotic treatment: a comparison between patients treated with clozapine or olanzapine // NeuroEndocrinolLett. – 2012. – Vol. 33 (5). – P. 493–498.

5. Newcomer J.W. Medical risk in patients with bipolar disorder and schizophrenia // J Clin Psychiatry. – 2006. – Vol. 67 (9). – P. 25–30; discussion 36–42.

6. Yan H., Chen J.D., Zheng X.Y. Potential mechanisms of atypical antipsychotic-induced hypertriglyceridemia // Psychopharmacology (Berl). – 2013. – Vol. 229 (1). – P. 1–7. – DOI: 10.1007/s00213-013 3193-7

7. Casey D.E., Haupt D.W., Newcomer J.W. et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia // J Clin Psychiatry. – 2004. – Vol. 65 (7). – P. 4–18.

8. Brown RR, Estoup MW. Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine // IntClinPsychopharmacol. – 2005. – Vol. 20. – P. 105–112.

9. Kudla D., Lambert M., Domin S. et al. Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: results of a multi-centre observational trial // Eur Psychiatry. – 2007. – Vol. 22 (3). – P. 195–202.

10. Smirnova L.P., Parshukova D.A., Borodiuk I.N. et al. Lipid spectrum changes and ECG in patients with paranoid schizophrenia in the course of therapy with atypical antipsychotics // ZhNevrolPsikhiatrIm S SKorsakova. – 2015. – Vol. 115 (3). – P. 49–53.

11. Wang Y., Liu F., Li L. [et al.]. The association between apolipoprotein A1-C3-A5 gene cluster promoter polymorphisms and risk of ischemic stroke in the northern Chinese Han population // J Int Med Res. – 2017. – Vol. 45 (6). – P. 2042–2052. – DOI: 10.1177/0300060517713517

12. Klimov A.N., Nikul'cheva N.G. Obmenlipidovilipoproteidovi ego narusheniya: rukovodstvodlyavrachej. – SPb., 1999. – 505 s.

13. RebrovaO.Yu. Statisticheskijanalizmedicinskihdannyh.Primeneniepaketaprikladnyhprogramm STATISTICA. – M.: MediaSfera, 2002. – 312 s.

14. Yarovaya E.B., Vazhkij D.G., Metel'skaya V.A. Obratnyj transport holesterinaizkletok: postroenieianalizregressionnyhmodelejdlyaocenki ego effektivnosti // Membrany. Ser. Kriticheskietekhnologii. – 2003. – № 3 (19). – S. 13–19.

15. Chen E.S. Apolipoprotein A1 gene polymorphisms as risk factors for hypertension and obesity // ClinExp Med. – 2009. – Vol. 6. – P. 32–36.

16. Perez-Iglesias R., Mata I., Pelayo-Teran J.M. et al. Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population // Schizophr Res. – 2009. – Vol. 107 (2–3). – P. 115–121.

17. Tsai M.Y., Chang C.M., Huang T.L. Changes in high-density lipoprotein and homeostasis model assessment of insulin resistance in medicated schizophrenic patients and healthy controls // Chang Gung Med J. – 2010. – Vol. 33(6). – P. 613–618.

18. Medved V. Kuzman M.R., Jovanovic N. et al. Metabolic syndrome in female patients with schizophrenia treated with second generation antipsychotics: a 3-month follow-up // J Psychopharmacol. – 2009. – Vol. 23 (8). – P. 915–922.

19. Lauressergues E., Martin F., Helleboid A. et al. Overweight induced by chronic risperidone exposure is correlated with overexpression of the SREBP-1c and FAS genes in mouse liver // NaunynSchmiedebergs Arch Pharmacol. – 2011. – Vol. 383 (4). – P. 423–436. DOI: 10.1007/s00210-010-0597-3

20. Tsai M.Y., Ordovas J.M. APOC3 mutation, serum triglyceride concentrations, and coronary heart disease // Clin Chem. – 2009. – Vol. 55 (7). – P. 1274–1276. – DOI: 10.1373/clinchem.2009.124669

21. Song Y.Y., Zhu L., Richa M. et al. Associations of the APOC3 rs5128 polymorphism with plasma APOC3 and lipid levels: a meta-analysis // Lipids Health Dis. – 2015. – Vol. 14. – P. 32. – DOI: 10.1186/s12944-015-0027-0

22. Sun Q., Cornelis M.C., Kraft P. et al. Genome-wide association study identifies polymorphisms in LEPR as determinants of plasma soluble leptin receptor levels // Hum Mol Genet. – 2010. – Vol. 19 (9). – P. 1846–1855.